Welcome to our dedicated page for Lifevantage news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage stock.
LifeVantage Corporation reports developments for a health and wellness company built around nutrigenomics, dietary supplements, skin and hair care products, nootropic energy drink mixes, and pet supplements. Its product line includes Protandim, TrueScience Liquid Collagen, MindBody GLP-1 System, LoveBiome P84, AXIO, TrueScience skin and hair care products, and Petandim, sold through independent Consultants to customers.
Company news commonly covers quarterly results, regional sales trends, product innovation, patents tied to cellular-signaling supplement compositions, consultant events and training, international market expansion, executive leadership changes, share repurchases, and cash dividends. Updates also describe capital allocation and the company’s direct-selling business model.
LifeVantage Corporation (Nasdaq: LFVN) reported its first quarter fiscal 2021 results, achieving adjusted EPS of $0.25, up 92.3% year-over-year. Total revenue reached $54.8 million, a 2.5% decline from the previous year, primarily due to the absence of an Elite Academy event. Active accounts decreased by 3.9% sequentially. Gross profit was $45.4 million, 82.9% of revenue. Adjusted EBITDA increased by 42.5% to $6.7 million. The company maintains a strong balance sheet with $18 million in cash and no debt. Guidance for fiscal 2021 remains unchanged, projecting revenue of $240-$251 million.
LifeVantage Corporation (Nasdaq: LFVN) will announce its financial results for the first quarter ended September 30, 2020, on November 3, 2020, after market close. A conference call for investors is scheduled for 2:30 p.m. MT. Interested participants can join by calling (877) 705-6003, with a replay available until November 10. The event will also be webcast live on the company's website. LifeVantage specializes in Nutrigenomics, offering a variety of nutraceutical supplements and skin care products, including its popular Protandim® line.
LifeVantage Corporation (Nasdaq: LFVN) announced the resignation of CEO Darren Jensen on September 3, 2020, with Chief Financial Officer Steven Fife appointed as the interim CEO. The Board is seeking a permanent successor. The company's sales and marketing teams will merge, led by Chief Sales Officer Justin Rose. LifeVantage reaffirmed its fiscal 2021 guidance, expecting revenue of $240 million to $251 million, adjusted EBITDA of $25 million to $27 million, and adjusted earnings per share between $0.87 and $0.91, while noting potential impacts from the evolving COVID-19 pandemic.
LifeVantage Corporation (Nasdaq: LFVN) announced that CEO Darren Jensen and CFO Steve Fife will participate in two upcoming virtual investor conferences. The LD Micro 500 conference is scheduled for September 1-4, with a presentation on September 2 at 9:20 a.m. MT. They will also attend the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, presenting on September 15. Both presentations will be available via webcast on the company’s investor relations website.
LifeVantage Corporation (Nasdaq: LFVN) reported record fiscal 2020 revenue of $233 million, marking a 3.1% increase year-over-year. The fourth quarter alone generated $59.4 million in revenue, a 5.7% increase from the previous year. Adjusted EBITDA rose 31.3% to $24 million. The company ended the fiscal year with strong cash flow, holding $22.1 million in cash and zero debt. Earnings per share for fiscal 2020 were $0.79, up from $0.50 in fiscal 2019. Looking ahead, the company expects $240 million to $251 million in revenue for fiscal 2021.
LifeVantage Corporation (Nasdaq: LFVN) reported third-quarter fiscal 2020 revenue of $56.1 million, a slight increase from the previous year. Adjusted EBITDA rose 26.4% to $5.1 million. Revenue in the Americas declined 0.5%, while Asia/Pacific & Europe saw a 1.6% increase. Total active accounts decreased 3.8% sequentially. Q3 earnings per diluted share were $0.11, compared to $0.12 last year. The company reiterated adjusted EPS guidance of $0.74 to $0.79 for fiscal 2020, anticipating revenue will fall below earlier estimates due to the pandemic.